HC Wainwright Begins Coverage on Galectin Therapeutics (NASDAQ:GALT)

Analysts at HC Wainwright began coverage on shares of Galectin Therapeutics (NASDAQ:GALT - Get Free Report) in a report released on Tuesday, MarketBeat.com reports. The brokerage set a "buy" rating and a $6.00 price target on the stock. HC Wainwright's price target would indicate a potential upside of 82.37% from the company's current price. HC Wainwright also issued estimates for Galectin Therapeutics' Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.67) EPS, FY2026 earnings at ($0.65) EPS and FY2027 earnings at ($0.72) EPS.

Galectin Therapeutics Stock Performance

Shares of Galectin Therapeutics stock traded up $0.90 on Tuesday, reaching $3.29. 5,373,018 shares of the company were exchanged, compared to its average volume of 388,765. The company's 50-day moving average is $1.43 and its two-hundred day moving average is $1.44. The firm has a market cap of $208.22 million, a price-to-earnings ratio of -4.57 and a beta of 0.54. Galectin Therapeutics has a 1-year low of $0.73 and a 1-year high of $3.30.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.05. As a group, sell-side analysts forecast that Galectin Therapeutics will post -0.73 earnings per share for the current year.

Institutional Trading of Galectin Therapeutics

Several large investors have recently added to or reduced their stakes in GALT. Y Intercept Hong Kong Ltd acquired a new stake in Galectin Therapeutics in the 1st quarter valued at approximately $287,000. LPL Financial LLC increased its position in Galectin Therapeutics by 69.6% in the 4th quarter. LPL Financial LLC now owns 138,928 shares of the company's stock valued at $179,000 after acquiring an additional 57,020 shares during the period. HighTower Advisors LLC increased its position in Galectin Therapeutics by 244.1% in the 1st quarter. HighTower Advisors LLC now owns 77,375 shares of the company's stock valued at $94,000 after acquiring an additional 54,889 shares during the period. Geneos Wealth Management Inc. increased its position in Galectin Therapeutics by 8.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 423,235 shares of the company's stock valued at $516,000 after acquiring an additional 34,300 shares during the period. Finally, JPMorgan Chase & Co. increased its position in Galectin Therapeutics by 94.9% in the 4th quarter. JPMorgan Chase & Co. now owns 59,693 shares of the company's stock valued at $77,000 after acquiring an additional 29,065 shares during the period. 11.68% of the stock is currently owned by institutional investors and hedge funds.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.